Pre-Test Targeting IL-23 in IBD: Updates in Emerging Therapies and Patient-Centered Care Pre-Test According to current data, approximately what percentage of patients are primary non-responders? 10% - 20% 10% - 30% 20% - 30% 20% - 40% Unsure Which of the following cytokines promotes the induction of a Th17 immune response and the production of inflammatory cytokines involved in IBD pathogenesis? TNF-a IL-17 IL-21 IL-23 Unsure Data from the SUCCESS consortium demonstrated that bio-naïve IBD patients treated with _______, saw higher rates of clinical and endoscopic remission. Brazikumab Guselkumab Risankizumab Ustekinumab Unsure A comparative safety cohort study demonstrated that ustekinumab treatment was associated with a lower risk of which AE, compared to TNF-a antagonists? Anemia Rashes Risk of serious infection Risk of hospitalization Unsure How confident are you in your ability to utilize shared decision-making strategies to individualize patient care? Very confident Confident Somewhat confident Not very confident Not at all confident
